Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model

被引:32
作者
Reis, A
Reinhard, T
Sundmacher, R
Braunstein, C
Godehardt, E
机构
[1] Heinrich Heine Univ, Augenklin, D-40225 Dusseldorf, Germany
[2] Univ Dusseldorf, Dept Pathol, D-4000 Dusseldorf, Germany
[3] Univ Dusseldorf, Dept Biometry, Dept Cardiac & Thorac Surg, D-4000 Dusseldorf, Germany
关键词
D O I
10.1136/bjo.82.6.700
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aims-To compare the effectiveness of mycophenolate mofetil (MMF), cyclosporin A (CSA), and both in combination, in preventing rejection following corneal transplantations. Methods-Rats of the inbred strains Brown Norway and Lewis were used as donors and recipients respectively. MMF was administered orally in both monotherapy and combination therapy for 14 days in a dosage of 40 mg/kg body weight, and CSA was administered, likewise for 14 days, in an intramuscular dosage of 10 mg/kg body weight. The transplants were examined every third day by slit lamp microscopy. Every transplant was subjected to histological or immunohistological evaluation. Results-The average transplant survival rate in the allogenic strain combination was 7.9 days (SEM 1.1). Monotherapy with MMF led to a statistically significant prolongation of transplant survival to 11.6 days (SEM 0.9, p< 0.05). Monotherapy with CSA delayed transplant rejection statistically significantly longer than MMF (21 days, 0.0, p< 0.05). The combination therapy with CSA and MMF was statistically significantly superior to the monotherapy with MMF (22.3 days, 0.5, p< 0.05). The combination therapy prolonged transplant survival compared with the CSA monotherapy, albeit not to a statistically significant extent. Conclusions-In this study we were able to prove the immunosuppressive effect of oral MMF on acute rejection following corneal transplantation. Double drug therapy with CSA and MMF conferred a marginal benefit without a higher incidence of complications related to drug toxicity or overimmunosuppression.
引用
收藏
页码:700 / 703
页数:4
相关论文
共 14 条
[1]  
Allison A C, 1977, Ciba Found Symp, P207
[2]  
DEIERHOI MH, 1993, TRANSPLANT P, V25, P693
[3]  
GRINYO J, 1995, LANCET, V345, P1321
[4]  
HERBORT CP, 1989, JPN J OPHTHALMOL, V33, P212
[5]  
Hikita N, 1997, INVEST OPHTH VIS SCI, V38, P901
[6]   TACROLIMUS, A NEW IMMUNOSUPPRESSANT - A REVIEW OF THE LITERATURE [J].
HOOKS, MA .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (04) :501-511
[7]  
MORRIS RE, 1990, TRANSPLANT P, V22, P1659
[8]  
Niederkorn JY, 1996, INVEST OPHTH VIS SCI, V37, P2700
[9]  
OLSEN TW, 1994, INVEST OPHTH VIS SCI, V35, P1877
[10]   Systemic ciclosporin A in high-risk keratoplasties [J].
Reinhard, T ;
Sundmacher, R ;
Heering, P .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1996, 234 :S115-S121